Chelsea Therapeutics International Ltd

Chelsea Therapeutics International — Investor Presentation (September 2011)

28 slides from Chelsea Therapeutics International's investor presentation, Sep 13, 2011

  1. Slide 1: Chelsea Therapeutics, September 2011

    Slide 1: Chelsea Therapeutics, September 2011

    Exhibit 99.1 Exhibit September © 2004-2011 99.12011 Chelsea Therapeutics, Inc.

  2. Slide 2: Forward-Looking Statement

    Slide 2: Forward-Looking Statement

    Forward-Looking appropriateness This materially. clinical Exchange NASDAQ: presentation trials, Commission. These CHTP intellectual orrisks isStatement contains suitability being andproperty provided forward-looking uncertainties of anyrisks, for investment. informational include andstatements the f

  3. Slide 3: Overview: Two Major Late-Stage Assets

    Slide 3: Overview: Two Major Late-Stage Assets

    Two Major Overview Neurogenic Droxidopa: Intradialytic Freezing Other Rheumatoid Psoriasis Non-Metabolized Five Phase *Approved NASDAQ: Clinical norepinephrine III of Crohn’s Trial: Assets CHTP indication Gait* Orthostatic Arthritis Hypotension* Trials Falls Disease Antifolates: Chronic Targeting Ex

  4. Slide 4: Northera Overview

    Slide 4: Northera Overview

    Northera™ Oral Within •Well NASDAQ: Replenishes Unique Only Marketed Orthostatic Freezing Hypotension “Prodrug”of Documented Chronic Autonomic Mechanism ofEx CHTP Overview Hypotension Gait Diminished associated US Oral Norepinephrine: in Safety (Japan) Nervous Therapy Parkinson’s of Action and with

  5. Slide 5: Lead Indication: Neurogenic Orthostatic Hypotension

    Slide 5: Lead Indication: Neurogenic Orthostatic Hypotension

    Lead Neurogenic ••Symptoms •Caused •Three NASDAQ: SomeIndication: Primary patients by CHTP Diminished include Orthostatic Patient cannot Neurogenic dizziness, stand Groups: Hypotension Synthesis Orthostatic unaided lightheadedness, Parkinson’s and/or (NOH): for Hypotension more Release disease Sudde

  6. Slide 6: NOH: Current Therapeutic Landscape

    Slide 6: NOH: Current Therapeutic Landscape

    NOH: •Poor *Verispan, NASDAQ: Alpha Not Surrogate Provides Black piloerection Poor $55-60M approved Current patient penetration box agonist constant/undifferentiated 2007 peak CHTP warning (goose persistence Therapeutic at for side sales Best: of symptomatic effects for bumps, PD (priced Midodrine s

  7. Slide 7: NOH: Parkinson's Disease Target Market

    Slide 7: NOH: Parkinson's Disease Target Market

    NOH: •Parkinson’s Target PD PAF MSA NASDAQ: Approximately 3 Primary Pure 2,000 Multiple 25,000-75,000 80% Estimated 60,000 Limited >=<<=15% Autonomic suffer Market Patient 5% 80% patients new Use System CHTP Patient 700,000 Disease from patients Population: of Expansion inMSA 20% Midodrine Failure A

  8. Slide 8: Northera: Attractive Commercial Opportunity

    Slide 8: Northera: Attractive Commercial Opportunity

    Northera: Attractive Limited Personal •Non-Personal NASDAQ: Accounts Chronic Price: Compliance: 10% ~4,000 No Promotional Medical Journal Direct Sampling Competing of$30/day Sales Mail Physicians Promotion: Advertising Midodrine Treatment US Science US for Program Programs CHTP Educational Commercia

  9. Slide 9: Northera NDA Status

    Slide 9: Northera NDA Status

    Northera •New •Study NASDAQ: Anticipating FDADrug Fast StudyTrack 301: 302: confirms 304: 305: 303: NDA: Pivotal Supporting CHTP Application: Status 24Priority Long-Term HR Neurogenic 301Proof Blood and Review, Phase Q3 Safety supportive ofPressure Efficacy Orthostatic 2011 IIIEstimated Extension Ef

  10. Slide 10: Study 301 Results

    Slide 10: Study 301 Results

    Study Difference (in Head Concentration Fatigue Weakness Vision Dizziness OHQ-Composite 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 OHSA Standing Walking pOHDAS-Composite Favors NASDAQ: 10<= Change 0.05 0.01 0.001 &301: Composite Northera Placebo Neck Short Long Short Long Between Symptoms from CHTP Pain Time T

  11. Slide 11: Study 302 Results

    Slide 11: Study 302 Results

    Study Difference (in Head Concentration Fatigue Weakness Vision Dizziness -0.50 -0.25 0.00 0.25 0.50 0.75 1.00 1.25 1.50 OHSA Standing *Walking OHQ-Composite OHDAS-Composite Favors NASDAQ: 11p<0.05 Change &302: Composite Northera Placebo Neck Short Long Short Long **Between Symptoms from CHTP p<0.01

  12. Slide 12: Study 302 Safety

    Slide 12: Study 302 Safety

    Study •Most #Placebo (# SAEs Any Definitely Relatedness Probably Possibly Unlikely Not Severe Severity Moderate Mild NASDAQ: Headache: Falls: patients events) Related AEs 12 common 0301 06.8 (0) Northera (21) Related (0) Related Related 14 4% (# Related &% 0CHTP (7) 73.0 0(28) #events) 14.8 302: 0pl

  13. Slide 13: Expanding Label: Falls in Parkinson's Disease

    Slide 13: Expanding Label: Falls in Parkinson's Disease

    Expanding Injuries #1 2nd •Estimated NASDAQ: leading 1/3 NOH reason most of (symptomatic PD sustained cause common for 20% the CHTP related patients Label of in death patients reason nursing falls in & being Parkinson’s in non-symptomatic) are for with the home admitted aPD elderly common Parkinson’

  14. Slide 14: Northera Preliminary Data: Study 306

    Slide 14: Northera Preliminary Data: Study 306

    Northera PreliminaryData Preliminary, Data Study Data: •Future NASDAQ: Anticipate Target To FDA Powering be safety Mid 306A: 306B: Confirmed Studies initiated Enrollment: sNDA: 2012 for CHTP monitoring top unblinded Supporting Phase to approximately line post-approval, Reported Reduction Support Sui

  15. Slide 15: Study 306A: Total Falls

    Slide 15: Study 306A: Total Falls

    Studyfalls Northera 70 60 40 30 20 10 25 50 75 100 125 150 175 200 225 Total Number NASDAQ: 306A: of (n=24) =Days Falls CHTP 197 79 Cumulative Placebo of Therapy (n=27) Falls

  16. Slide 16: Capturing Falls: Daily Diary

    Slide 16: Capturing Falls: Daily Diary

    Capturing Each •In NASDAQ: A Activities Location Symptoms Injury, ON Recent addition fall patient orisOFF amnesia, changes defined Falls: and to surrounding CHTP prior prompted (ON the familiarity Ato number as hospitalization to -Daily Having PD UNEXPECTANTLY falltomedications fall (lightheadedness

  17. Slide 17: Study 306A: Falls per Patient/Week

    Slide 17: Study 306A: Falls per Patient/Week

    Study •Falls 2.3 Mean NASDAQ: Placebo Droxidopa 0.93 0.39 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Allows Detailed Fold per Falls 306A: or for patient/week discussion 60% CHTP / distribution Patient Reducing Reduction / of Week pre-specified Falls metric of falls inper Falls and to patient/week b

  18. Slide 18: Study 306A: Change in Hoehn & Yahr Score

    Slide 18: Study 306A: Change in Hoehn & Yahr Score

    Study •Commonly Change Baseline NASDAQ: Placebo Droxidopa -0.6 -0.4 -02 -0.0 heavily 306A: into weighted HY CHTP End-of-Treatment used Improving Score 5-point towardHoehn rating postural scale & Yahr instability characterizing Scoresas thethe primary progression index of Parkinson’s disease severity

  19. Slide 19: Study 306A: MDS-UPDRS Change

    Slide 19: Study 306A: MDS-UPDRS Change

    Study Assessing 0-Change Placebo Droxidopa -0.62 -1.88 -3.00 -2.78 -4.88 -4.96 -6.33 -8 -6 -4 Part NASDAQ: 2 IV: I Part I: II: III: 306A: Non-Motor Motor in Motor the II Component CHTP Part Response severity Experiences Complications Examination III Experiences Part of Score inIV motor Parkinson’s o

  20. Slide 20: Study 306A: Efficacy in Repeat Fallers

    Slide 20: Study 306A: Efficacy in Repeat Fallers

    Study >40% 54321Improvement 1.9 2.0 0-1.3 10 -20.5 -15.8 1.7 -16.0 -30 -20 Change (Baseline Falls Falls>=2 Placebo Droxidopa -0.21 -0.40 0.27 -0.33 -1.0 -0.5 0.0 0.5 1.0 NASDAQ: 10 .4 0-1 306A: ofinpatients toHY MDS-UPDRS CHTP End-of-Treatment) Efficacy inScore Dizziness in Study in Repeat Score 306

  21. Slide 21: Study 306B: Next Steps

    Slide 21: Study 306B: Next Steps

    Study •Powering NASDAQ: Anticipate Target Primary 306B: 306B total outcome: for CHTP top Next enrollment: 45% line Steps reduction falls data per during 160patient inpatients the Q2number 2012 / week of falls per patient / week

  22. Slide 22: Droxidopa: Future Growth Opportunities

    Slide 22: Droxidopa: Future Growth Opportunities

    Droxidopa: Norepinephrine Intradialytic Fibromyalgia Adult 15-25% Droxidopa Chronic 2nd Debilitating CHTP: Completed Investigator: Data: Future NASDAQ: Most YE Q2 2011 Attention Growth Phase of Fatigue Pain 11 Common all +CHTP Label Fatigue Hypotension Phase Carbidopa Disorder II hemodialysis Opport

  23. Slide 23: Non-Metabolized Novel Antifolates

    Slide 23: Non-Metabolized Novel Antifolates

    Non-Metabolized Novel •Methotrexate NASDAQ: Additional Non-metabolized Potential Limitations Nausea Kidney Undergoes Est. 1/3 Antifolate and ofFirst CHTP MTX High significant are Diarrhea Liver (MTX) Line AEs with Antifolates Potential Patients Oral Toxicity and remains and Blockbuster metabolism An

  24. Slide 24: Developing Better, Safer Methotrexate

    Slide 24: Developing Better, Safer Methotrexate

    Developing H MTX (7-OH CH-4051 C (no NH2 Polyglutamylated CH 2N O NASDAQ: OH no H3 H-4051 2N HNchange!) O OH ONNH MTX OH H2N NONHCHTP O NaONBetter, CH2 NN OOHOH MTX Safer 3 and/or Methotrexate 7-OH MTX NH2 NH

  25. Slide 25: CH-4051: Phase II Proof-of-Concept

    Slide 25: CH-4051: Phase II Proof-of-Concept

    CH-4051: Phase 8-fold Superior Key Demonstrated 20-fold Improved 2-fold NASDAQ: preclinical findings II Improvement Higher Proof-of-Concept Efficacy: Safety/toxicity: Tolerability pharmacokinetics: Greater CHTP from Comparable safety Doses findings Efficacy, Superior phase in : Than inBioavailabilit

  26. Slide 26: CH-4051 Phase II Study Design

    Slide 26: CH-4051 Phase II Study Design

    •CH-4051 Randomization Screening N= Baseline 0.3 3.0 20 Hybrid Follow Up MTX Double-Blind NASDAQ: Staggered Enroll Open Un-blinded Full mg/wk to mg 50Washout data 2N= All ACR CH-4051/daily Up weeks 10 Visit Phase MTX 50 set: Arms Patients CHTP start: Score Interim N= Treatment 2Mid Visit II: weeks +

  27. Slide 27: Financial Summary and Capitalization

    Slide 27: Financial Summary and Capitalization

    Financial Capitalization Fully 3,241,550 Cash Warrants March $4.5 NASDAQ: million and Diluted70,786,680 2012 Options Expiring Short-Term Summary 5,697,430 CHTP – (as Exercise of (cash 7/26/11) Investments price exercise): $5.66—Anticipated Common( as ofStock 6/30/11)$67.1 61,847,700million

  28. Slide 28: Looking Ahead: Upcoming Milestones

    Slide 28: Looking Ahead: Upcoming Milestones

    Looking •Operational Upcoming Initiate Interim File Un-blinded Anticipated Top-line NASDAQ: Advance Drive Execute Northera CH-4051 Northera Analysis: Ahead…. Results Strategic, CH-4051 Milestones CHTP Interim US Focus NDA: Approval Droxidopa Northera Registration PII: NOHEfficacy Cash NOH inRA RA St

Source: SEC EDGAR · 8-K filed Sep 13, 2011

More decks from Chelsea Therapeutics International Ltd